After the Federal Drug Administration (FDA) pulled Zantac and other ranitidine products from the market for cancer-causing risks, many have questions about the unsafe nature of these drugs.
Ranitidine in the News
Zantac is a popular antacid and antihistamine medication used to treat various conditions such as acid reflux, heartburn, and stomach ulcers. Effective dosages of Zantac vary between 75 and 150 mg; however, some patients take a once-daily 300 mg tablet.
The active ingredient in Zantac is ranitidine, which decreases the amount of acid in the stomach. However, the drug also contains N-Nitrosodimethylamine (NDMA), which has been identified as a possible human carcinogen by multiple health organizations, including the U.S. Food and Drug Administration (FDA) and World Health Organization (WHO).
Since the 1980s, numerous studies have demonstrated mounting evidence of a very direct correlation between the NDMA in Zantac and cancer. However, manufacturers continued to market and profit from ranitidine medications, while concealing adverse side effects.
Our firm is here to fight for those who developed cancer from using Zantac. We will hold manufacturers and other responsible parties accountable for their disregard for human health and safety.
In September 2019, the FDA announced that it was further investigating Zantac cancer risks after testing 150 Zantac tablets and discovering that the medication contained NDMA amounts that were 3,000 times greater than the FDA-approved daily limit.
Contact a Zantac Cancer Attorney
If you or a loved one developed cancer or another medical condition from taking Zantac, McNabola & Associates is here to help you pursue legal action. We have successfully helped clients obtain justice for injuries and deaths related to defective and dangerous drugs.
You deserve compensation for the damages you incurred, and we will fight relentlessly to help you obtain a fully financial recovery.
Contact our firm at (312) 888-8700 to schedule your free case evaluation.
